Aristeia Capital’s Evolent Health EVH Stock Holding History

Aristeia Capital’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-21,900	Closed	-$437K	–	53
2018 Q4	$437K	Buy	+21,900	New	+$507K	0.03%	47

Other funds holding EVH

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Aristeia Capital's EVH Position: Q1 2019 in Review

Aristeia Capital sold out of Evolent Health (EVH) in Q1 2019, closing a stake of 21,900 shares — an estimated $437K sold.

Aristeia Capital first reported a position in EVH in Q4 2018 and held it in 1 quarter. The position peaked at $437K in Q4 2018. 192 funds tracked by Wall St. Rank hold EVH as of Q1 2019.

Aristeia Capital reported no remaining Evolent Health position as of Q1 2019 after selling out during the quarter.
Aristeia Capital sold 21,900 Evolent Health shares in Q1 2019, an estimated $437K.
Aristeia Capital first reported a position in Evolent Health in Q4 2018 and held it in 1 quarter.
Aristeia Capital's Evolent Health position peaked at $437K in Q4 2018.
192 funds tracked by Wall St. Rank held Evolent Health as of Q1 2019.

Based on Aristeia Capital's 13F filing for Q1 2019, filed 16 May 2019.